Renal Cancer - Results from #2140

Plasma KIM-1 is associated with recurrence risk after nephrectomy for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805). April 12, 2021

A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma. April 9, 2021

Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. April 9, 2021

3D-Image guided robotic-assisted partial nephrectomy: a multi-institutional propensity score-matched analysis (UroCCR study 51). April 8, 2021

Urinary Volatilomics Unveils a Candidate Biomarker Panel for Noninvasive Detection of Clear Cell Renal Cell Carcinoma. April 8, 2021

Subgroup-Independent Mapping of Renal Cell Carcinoma-Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries. April 7, 2021

Global Characterization of Immune Infiltration in Clear Cell Renal Cell Carcinoma. April 7, 2021

Impact of Radical Nephrectomy and Partial Nephrectomy on Actual Estimated Overall Survival Compared to Life Expectancy in Patients with Renal Cell Carcinoma. April 6, 2021

Oncological outcomes of active surveillance and percutaneous cryoablation of small renal masses are similar at intermediate term follow-up. April 6, 2021

Should patients with low risk renal cell carcinoma be followed differently after nephron-sparing surgery versus radical nephrectomy? April 5, 2021

Lenvatinib with or without everolimus in patients with metastatic renal cell carcinoma after immune checkpoint inhibitors and VEGFR-TKI therapies. April 5, 2021

Trans-ethnic variation in germline variants of patients with renal cell carcinoma. April 2, 2021

Lymph node dissection during radical nephrectomy: A Canadian multi-institutional analysis. April 2, 2021

Selective Suturing or Sutureless Technique in Robot-assisted Partial Nephrectomy: Results from a Propensity-score Matched Analysis. April 1, 2021

Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. April 1, 2021

Pegilodecakin as Monotherapy or in Combination with anti‐PD‐1 or Tyrosine Kinase Inhibitor in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma: Final Results of Cohorts A, G, H and I of IVY Phase I Study March 31, 2021

Diagnostic renal mass biopsy is associated with individual categories of PADUA and RENAL nephrometry scores: Analysis of diagnostic and concordance rates with surgical resection. March 31, 2021

A qualitative framework of non-selection factors for cytoreductive nephrectomy. March 31, 2021

Clear cell papillary renal cell carcinoma: Characteristics and survival outcomes from a large single institutional series. March 30, 2021

Increased risk for renal cell carcinoma in end stage renal disease - a population-based case-control study. March 30, 2021

Page 108 of 458